-
Royalty Pharma Reports Second Quarter 2025 Results
06 Aug 2025 11:00 GMT
… /Cometriq
Exelixis, Ipsen, Takeda
Cancer
20
17 … , Ferring Pharmaceuticals announced U.S. Food and Drug Administration ( … funding arrangement with Revolution Medicines. The funding arrangement includes … Cabometyx
In July 2025, Ipsen announced that the EC …
-
Ipsen (0MH6) Receives a Hold from Kepler Capital
02 Aug 2025 13:51 GMT
… maintained a Hold rating on Ipsen, with a price target of … success rate. Telliez covers the Healthcare sector, focusing on stocks such … , Abivax SA, and Adocia SA.
Ipsen has an analyst consensus of … of €129.00.
Based on Ipsen’s latest earnings release for …
-
Radius Pharmaceuticals Announces Victory in Patent Infringement Case Against Orbicular Pharmaceutical Technologies for Osteoporosis Treatment TYMLOS(R)
31 Jul 2025 21:01 GMT
… and co-plaintiff Ipsen Pharma S.A.S. ("Ipsen") in a … the U.S. Food and Drug Administration for the treatment of … : CorporateCommunications@radiuspharm.com
SOURCE: Radius Health
View the original
press releaseon …
-
Ipsen delivers strong results in the first half of 2025 and upgrades its full-year guidance
31 Jul 2025 05:00 GMT
… On 23 July 2025, Ipsen received European Commission approval … focus on bringing transformative medicines to patients in three … medicines to patients in more than 80 countries. Ipsen … For more information, visit ipsen.com. IPSEN CONTACTS Investors
Khalid Deojee …
-
Ipsen publie de solides résultats au premier semestre 2025 et relève ses objectifs financiers annuels
31 Jul 2025 05:00 GMT
… , sera disponible sur ipsen.com (section information réglementée … mise au point de médicaments innovants pour les … médicaments aux patients dans plus de 80 pays. Ipsen … 'informations, consultez ipsen.com. IPSEN CONTACTS Investisseurs Khalid Deojee …
-
Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
24 Jul 2025 21:42 GMT
… 2016, Exelixis granted Ipsen Pharma SAS exclusive rights for … medicines and regimens at the forefront of cancer care. Powered by drug … clevelandclinic.org/health/;diseases/22006 … .clevelandclinic.org/health/;diseases/22103- …
-
Europe Pharmaceutical Drugs Market Expands with R&D Innovation, Biologics Growth, and Regulatory Harmonization 2025–2032
10 Jul 2025 08:24 GMT
… The Europe pharmaceutical drugs market displays regional differences influenced by healthcare policies, … #47;S
» Merck KGaA
» Ipsen S.A.
» UCB S.A … Personalized and precision medicine continue to reshape the Europe pharmaceutical drugs market, with …
-
The Escalator: Novartis, Avalere Health, Ipsen and more
24 Jul 2025 12:06 GMT
…
The Food and Drug Administration named George … head of medical strategy and transformation.
Ipsen made a … immediately.
Board appointments:
Medicus Pharma added former Congresswoman Cathy … World Health Organization’s 2024 International Health Regulations …
-
Ipsen Updates Executive Committee
23 Jul 2025 16:08 GMT
… Region at Ipsen, Scheiffele will now lead all medicines in Oncology … and Rare Disease at Ipsen. In … pipeline innovation for new medicines and lead global brands … International, Gerber will lead Ipsen’s operations in all …
-
Ipsen announces changes to its Executive Committee
23 Jul 2025 05:30 GMT
… Region at Ipsen, Mari Scheiffele will now lead all medicines in … fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation; global trends … in new-medicine development, including obtaining regulatory approval; Ipsen’s ability …
About
© 1995-2025